about
Inhibition of doxorubicin-induced senescence by PPARδ activation agonists in cardiac muscle cells: cooperation between PPARδ and Bcl6Doxorubicin-induced expression of LOX-1 in H9c2 cardiac muscle cells and its role in apoptosisMyostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment.Advanced Oxidation Protein Products-Modified Albumin Induces Differentiation of RAW264.7 Macrophages into Dendritic-Like Cells Which Is Modulated by Cell Surface Thiols.Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes.Platelet-dependent and procoagulant mechanisms in arterial thrombosis.p38 MAPK and JNK antagonistically control senescence and cytoplasmic p16INK4A expression in doxorubicin-treated endothelial progenitor cellsAdipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions.Moderate Increase of Indoxyl Sulfate Promotes Monocyte Transition into Profibrotic MacrophagesSublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.Cell-cell bond modulates vascular smooth muscle cell responsiveness to Angiotensin II.Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms.CD14CD16 monocyte subset levels in heart failure patients.CD16(+) monocyte subsets are increased in large abdominal aortic aneurysms and are differentially related with circulating and cell-associated biochemical and inflammatory biomarkersResveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development.Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging.High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.Intravenous nifedipine prevents ergonovine-induced myocardial ischemia in patients with stable effort angina.Thrombolytic therapy in refractory unstable angina: the role of Holter monitoring.Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure.Intense lipid peroxidation in premature clinical coronary atherosclerosis is associated with metabolic abnormalities.Increased neutrophil lifespan in patients with congestive heart failure.Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia.Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity.Ergonovine maleate test detects anginal patients with poorly reproducible exercise testsMaximal endothelial tissue plasminogen activator release is not impaired in patients with acute coronary syndromes before heparin treatmentPostprandial serum induces apoptosis in endothelial cells: Role of polymorphonuclear-derived myeloperoxidase and metalloproteinase-9 activityDirect relationship between cell density and FDG uptake in asymptomatic aortic aneurysm close to surgical threshold: an in vivo and in vitro studySoluble form of the endothelial adhesion molecule CD146 binds preferentially CD16+ monocytesRole of advanced oxidation protein products and Thiol ratio in patients with acute coronary syndromesTwo Takayasu arteritis patients successfully treated with rituximabIndoxyl Sulfate Induces Renal Fibroblast Activation through a Targetable Heat Shock Protein 90-Dependent Pathway
P50
Q28484007-D23B4FDF-FF3B-43B7-AD7B-AC7E1724F429Q28576387-22982AFA-2B74-4883-89E4-01B52356A8A4Q30358722-BD6986C4-F762-4DA5-8D0E-DDF91A8C1C75Q30363344-E968DA6D-8E68-4F60-9E86-328297FB3F41Q30411254-E17EF1ED-0039-4175-90A4-FCDA32CF36F2Q33635802-77D29BBF-5DB8-447A-B41C-365654ACB8FAQ33781038-63C991B1-50E4-438D-BD98-E0F70117F054Q33829331-A8563519-071D-44AD-ABF2-3179FC067405Q35939396-CC49ECA9-BAF1-45BA-887B-CB1CC5C1594FQ39785684-3279CD53-5B0A-4528-87E3-189675C06CCBQ39814855-4825A49A-BEC9-4BDE-84AA-E20935836627Q40364136-29DFD6C9-58B5-42E2-835C-1B29B8183D26Q41174781-7C969BD8-326E-46AC-939E-32EA2005B847Q41861504-529BA668-8D15-484E-B115-924FB53B64E7Q42108377-35C86D97-B3CC-4952-A8EE-E990033DCDEEQ42726442-6C7B16FA-8F95-48A9-B47B-282FDCB1B9BCQ42915820-554642B0-3F63-4F2A-9A5D-8CB7CB4F9BD0Q44007564-D8B2E807-DC23-428F-84F2-5157029A641AQ44226707-ADC5DC8A-92E8-4816-80D7-1832249B5AD6Q44317617-2CEA2FF8-2276-4A88-B569-92A9C3C54E20Q44514122-F6777780-B25D-4D28-9E9B-0ACD11C93E2FQ44765950-0780E252-EE11-44B1-B0B1-F4C4FD4E47C1Q46093168-EBEA2ED6-116B-4B1C-B9C3-19416C35E5CCQ49379857-F25A82A2-7F44-47BA-BBDD-E16EABBF51AAQ51525573-0C3C1146-456E-4F42-AC72-9208BDC2A70BQ68630324-4192BCAB-5F06-4299-BF1A-DAD817603FB6Q74223684-7DE060CB-1FB1-453C-8FCB-B4237B32890AQ80451560-7AC16B5B-BF10-4FE1-AB27-1787D8E67B9CQ82104764-9418DE9F-F562-4ABC-B954-4D58BC28ACDBQ83396655-900F87DA-A62B-478C-8A2C-5CA63D7C9F1FQ83766995-D3017F05-D9C9-4BBC-9B87-4BEA40C5B546Q87194915-A36919EC-6A23-48B2-94B5-98D8D320614BQ92618428-A35A95E7-79C8-4B88-B61B-CAF64545CB59
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giorgio Ghigliotti
@ast
Giorgio Ghigliotti
@en
Giorgio Ghigliotti
@es
Giorgio Ghigliotti
@nl
Giorgio Ghigliotti
@sl
type
label
Giorgio Ghigliotti
@ast
Giorgio Ghigliotti
@en
Giorgio Ghigliotti
@es
Giorgio Ghigliotti
@nl
Giorgio Ghigliotti
@sl
prefLabel
Giorgio Ghigliotti
@ast
Giorgio Ghigliotti
@en
Giorgio Ghigliotti
@es
Giorgio Ghigliotti
@nl
Giorgio Ghigliotti
@sl
P106
P1153
7003558421
P21
P31
P496
0000-0001-8484-542X